(J Am Heart Assoc. 2016;5:e002530 doi: [10.1161/JAHA.115.002530](10.1161/JAHA.115.002530))

Accompanying Appendices S1 through S8 are available at <http://jaha.ahajournals.org/content/5/1/e002530/suppl/DC1>

Introduction {#jah31280-sec-0004}
============

Diastolic dysfunction (DD) is an important cause of heart failure (HF) with preserved ejection fraction (pEF) and a major public health issue.[1](#jah31280-bib-0001){ref-type="ref"}, [2](#jah31280-bib-0002){ref-type="ref"}, [3](#jah31280-bib-0003){ref-type="ref"} Epidemiological studies indicate that varying severities of DD are present in the community.[1](#jah31280-bib-0001){ref-type="ref"} DD is predictive of developing overt HF and all‐cause mortality.[1](#jah31280-bib-0001){ref-type="ref"}, [3](#jah31280-bib-0003){ref-type="ref"}

Left ventricular (LV) end‐diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) is frequently used to assess LV diastolic function. Echocardiography is the mainstay for the noninvasive evaluation and quantitation of diastolic function.[4](#jah31280-bib-0004){ref-type="ref"}, [5](#jah31280-bib-0005){ref-type="ref"} Myocardial stiffness and relaxation abnormalities in DD result in elevated LVFP that is indirectly evaluated with echocardiography.[4](#jah31280-bib-0004){ref-type="ref"}, [5](#jah31280-bib-0005){ref-type="ref"} Early mitral annular velocity (è) obtained with the use of tissue Doppler imaging provides assessment of LV myocardial relaxation; è \<8 to 10 cm/s (based on the location lateral or septal annulus or mean of lateral and septal) is indicative of impaired myocardial relaxation.[4](#jah31280-bib-0004){ref-type="ref"}, [5](#jah31280-bib-0005){ref-type="ref"} In conjunction with mitral peak early filling velocity E, the ratio of E/è is used to estimate LVFP and its use is recommended by the American Society of Echocardiography (ASE) and European Society of Cardiology (ESC) for evaluating DD/HFpEF.[4](#jah31280-bib-0004){ref-type="ref"}, [5](#jah31280-bib-0005){ref-type="ref"} E/è~lateral~ \>12, E/è~mean~ \>13, or E/è~septal~ \>15 indicates elevated LVFP, whereas E/è \<8 (any location) indicates normal LVFP.[4](#jah31280-bib-0004){ref-type="ref"} When E/è falls into the intermediate zone (8\< E/è \<12--15), additional echocardiographic indices are used to estimate LVFP.[4](#jah31280-bib-0004){ref-type="ref"}, [5](#jah31280-bib-0005){ref-type="ref"}

E/è is extensively used both clinically and in multidisciplinary clinical research as a noninvasive surrogate for LVFP and diastolic function.[6](#jah31280-bib-0006){ref-type="ref"}, [7](#jah31280-bib-0007){ref-type="ref"}, [8](#jah31280-bib-0008){ref-type="ref"} However, its diagnostic accuracy is not well studied. We, therefore, decided to evaluate the diagnostic accuracy of E/è in evaluating LVFP and DD/HFpEF.

Methods {#jah31280-sec-0005}
=======

The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses statement and the *Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy*. The protocol for this review is described in Appendix S1.

Data Sources and Searches {#jah31280-sec-0006}
-------------------------

Original clinical studies that evaluated LVFP and DD/HFpEF by using echocardiography and invasive techniques were screened from PubMed, Scopus, Embase, and Cochrane Library databases to February 2015 through the use of a number of search strategies with assistance from the librarian (Appendix S2).

Study Selection {#jah31280-sec-0007}
---------------

We included studies that provided data on the diagnostic accuracy of pulsed‐wave tissue Doppler imaging index E/è to estimate LVFP and to identify DD/HFpEF.

*For primary analysis*, the studies were included if the participants had pEF cohort defined as ≥50% and corresponding echocardiographic E/è and invasive LVFP measurements at rest. The study had to evaluate the E/è--LVFP relationship and/or provide such data that a 2×2 table of true‐positive, false‐positive, false‐negative, and true‐negative values could be created for statistical analysis as described later. Table [1](#jah31280-tbl-0001){ref-type="table-wrap"} describes the characteristics of the preserved LVEF patient cohort and data for primary analysis from the selected studies.

###### 

Data for Primary Analysis[a](#jah31280-note-0003){ref-type="fn"}

  Study (Reference)                                                               LVEF, %   N     Age, y (mean±SD)   Indication for Catheterization                             Echo and Catheterization Timing   Correlation to LVFP      2×2 to Predict LVFP          2×2 to Predict DD/HFpEF (Composite Reference Test)[b](#jah31280-note-0004){ref-type="fn"}   Patient Comorbidities, %                                 
  ------------------------------------------------------------------------------- --------- ----- ------------------ ---------------------------------------------------------- --------------------------------- ------------------------ ---------------------------- ------------------------------------------------------------------------------------------- -------------------------------------------- ----- ----- -----
  Ommen et al (2000)[15](#jah31280-bib-0015){ref-type="ref"}                      \>50      64    ---                Clinically indicated                                       Simultaneous                      L, S, M (LVMDP)          S (LVMDP, from graph)        ---                                                                                         ---                                          ---   ---   ---
  Gonzalez‐Vilchez et al (2002)[16](#jah31280-bib-0016){ref-type="ref"}           \>50      32    66±13              Clinically indicated                                       Sequential                        L (PCWP)                 ---                          ---                                                                                         ---                                          ---   ---   ---
  Rivas‐Gotz et al (2003)[18](#jah31280-bib-0018){ref-type="ref"}                 ≥55       55    64±2               ICU or cath lab                                            Simultaneous                      L, S, M (PCWP)           L, S (PCWP, from graph)      ---                                                                                         ---                                          ---   ---   ---
  Dokanish et al (2004)[19](#jah31280-bib-0019){ref-type="ref"}                   ≥50       19    57±13              ICU or CCU                                                 Simultaneous                      ---                      M (PCWP, from graph)         ---                                                                                         ---                                          ---   58    21
  Mansencal et al (2004)[20](#jah31280-bib-0020){ref-type="ref"}                  \>50      20    66±10              Chest pain/CAD                                             ≤1 h                              L (Pre‐A)                L (Pre‐A, from graph)        ---                                                                                         5                                            100   5     ---
  Hadano et al (2005)[23](#jah31280-bib-0023){ref-type="ref"}                     \>50      65    66±9               Clinically indicated                                       ≤3 h                              L (LVEDP, PCWP)          L (PCWP, from graph)         ---                                                                                         ---                                          28    ---   ---
  Kidawa et al (2005)[24](#jah31280-bib-0024){ref-type="ref"}                     \>50      50    ---                Coronary angiography                                       Simultaneous                      L, S (LVEDP)             L (LVEDP, from graph)        ---                                                                                         ---                                          ---   ---   ---
  Kasner et al (2007)[26](#jah31280-bib-0026){ref-type="ref"}                     \>50      55    ---                43 exercise dyspnea/12 chest pain                          3 to 5 h                          L (LVEDP)                ---                          ---                                                                                         78                                           0     62    9
  Wang et al (2007)[29](#jah31280-bib-0029){ref-type="ref"}                       \>50      20    ---                ICU or cath lab                                            Simultaneous                      M (PCWP)                 ---                          ---                                                                                         ---                                          ---   ---   ---
  Dokanish et al (2008)[30](#jah31280-bib-0030){ref-type="ref"}                   \>50      32    ---                Dyspnea                                                    Sequential                        M (Pre‐A)                ---                          ---                                                                                         ---                                          ---   ---   ---
  Rudko et al (2008)[32](#jah31280-bib-0032){ref-type="ref"}                      \>50      39    64±5               Clinically indicated                                       Simultaneous                      S (LVMDP)                S (LVMDP, from graph)        ---                                                                                         23                                           77    51    ---
  Dini et al (2010)[33](#jah31280-bib-0033){ref-type="ref"}                       \>50      55    71±12              LV dysfunction                                             ≤1 h                              ---                      M (Pre‐A, from text)         ---                                                                                         100[c](#jah31280-note-0005){ref-type="fn"}   ---   ---   ---
  Dokanish et al (2010)[34](#jah31280-bib-0034){ref-type="ref"}                   ≥50       122   55±9               Coronary angiography                                       Sequential                        M (Pre‐A)                ---                          ---                                                                                         ---                                          65    88    55
  Dokanish et al (2010)[35](#jah31280-bib-0035){ref-type="ref"}                   ≥50       122   55±9               Coronary angiography                                       Sequential                        M (LVEDP)                M (LVEDP, from graph)        ---                                                                                         ---                                          65    88    43
  Kasner et al (2010)[37](#jah31280-bib-0037){ref-type="ref"}                     \>50      33    ---                21 exercise dyspnea/12 chest pain                          Simultaneous                      L (LVEDP)                ---                          ---                                                                                         64                                           0     61    9
  Penicka et al (2010)[38](#jah31280-bib-0038){ref-type="ref"}                    \>50      30    67±9               Chronic NYHA II/III dyspnea                                Simultaneous                      ---                      ---                          L, S, M (LVEDP, from text)                                                                  67                                           0     70    27
  Bhella et al (2011)[39](#jah31280-bib-0039){ref-type="ref"}                     \>50      11    73±7               Clinical research, HFpEF                                   Simultaneous                      M (PCWP)                 M (PCWP, from graph)         ---                                                                                         100                                          0     100   55
  Hsiao et al (2011)[40](#jah31280-bib-0040){ref-type="ref"}                      \>50      100   69±13              Coronary angiography                                       Sequential                        L, S, M (Pre‐A)          ---                          ---                                                                                         ---                                          100   72    47
  Maeder et al (2011)[42](#jah31280-bib-0042){ref-type="ref"}                     \>50      36    56±17              11 PAH/15 HF/10 healthy volunteers and atypical patients   Sequential                        L, S, M (PCWP)           ---                          ---                                                                                         42                                           ---   ---   ---
  Özer et al (2011)[43](#jah31280-bib-0043){ref-type="ref"}                       \>50      45    62±10              Coronary angiography                                       ≤24 h                             L, S, M (LVEDP)          L, S, M (LVEDP, from text)   ---                                                                                         ---                                          100   64    42
  Previtali et al (2012)[46](#jah31280-bib-0046){ref-type="ref"}                  ≥55       57    ---                Clinically indicated                                       ≤1 h                              L, S, M (LVEDP, Pre‐A)   L (LVEDP, from graph)        ---                                                                                         0                                            ---   ---   ---
  Manouras et al (2013)[48](#jah31280-bib-0048){ref-type="ref"}                   ≥55       38    ---                Coronary angiography                                       Simultaneous                      L, S, M (LVEDP, Pre‐A)   M (Pre‐A, from graph)        ---                                                                                         ---                                          0     ---   ---
  Hajahmadi Poorrafsanjani et al (2014)[50](#jah31280-bib-0050){ref-type="ref"}   ≥50       76    ---                Coronary angiography/mild valve disease                    Next day                          L (LVEDP)                ---                          ---                                                                                         ---                                          ---   ---   ---
  Tatsumi et al (2014)[51](#jah31280-bib-0051){ref-type="ref"}                    ≥50       22    65±18              Clinically indicated                                       Not reported                      S (PCWP)                 ---                          ---                                                                                         ---                                          ---   ---   ---

Empty cells are the result of no available data. 2×2 indicates set of true‐positive, false‐positive, false‐negative, and true‐negative values for recommended by American Society of Echocardiography E/è cutoffs; CAD, coronary artery disease; cath lab, catheterization laboratory; CCU, critical care unit; DD, diastolic dysfunction; DM, diabetes mellitus; HF, heart failure (clinical diagnosis); HTN, hypertension; ICU, intensive care unit; L, S, and M, lateral, septal, and mean E/è; LVEDP, left ventricular end‐diastolic pressure; LVEF, left ventricular ejection fraction; LVFP, left ventricular filling pressure; LVMDP, left ventricular mean diastolic pressure; N, number of patients; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PCWP, pulmonary capillary wedge pressure; pEF, preserved ejection fraction; Pre‐A, left ventricular pre--A wave diastolic pressure.

For primary analysis, the studies were included if the participants had preserved LVEF cohort defined as ≥50% and provided corresponding echocardiographic E/è and invasive LVFP measurements at rest. Further, data were available such that a 2×2 table of true‐positive, false‐positive, false‐negative, and true‐negative values could be created for statistical analysis.

Clinical DD/HFpEF was described in the study based on composite of clinical signs and symptoms of HF with invasive parameters of DD with preserved LVEF.

Patient group included HF stages B, C, and D.

*For secondary analysis*, we also included supplemental studies that either used a lower LVEF threshold to identify preserved LV systolic function (ie, LVEF ≥40% or 45%) or had no criteria for normal LVEF but the mean and SD for LVEF of the study satisfied the condition that mean minus 2 SDs ≥40%. For a normal distribution, the latter condition assumes that ≈98% of participants have LVEF ≥40%. This allowed for the inclusion of all clinically relevant studies for secondary analysis because LVEF between 40% and 50% is sometimes used to indicate pEF. Table [2](#jah31280-tbl-0002){ref-type="table-wrap"} describes the characteristics of the patient cohort and data for secondary analysis from the selected studies.

###### 

Data for Supplemental Analysis[a](#jah31280-note-0007){ref-type="fn"}

  Study (Reference)                                               LVEF, %   N     Age, y (mean±SD)   Indication for Catheterization                             Echo and Catheterization Timing   Correlation to LVFP      2×2 to Predict LVFP              2×2 to Predict DD/HFpEF (Composite Reference Test)[b](#jah31280-note-0008){ref-type="fn"}   Specific Reason for Excluding From Primary Analysis                            Patient Comorbidities, %               
  --------------------------------------------------------------- --------- ----- ------------------ ---------------------------------------------------------- --------------------------------- ------------------------ -------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ -------------------------- ----- ----- -----
  Nagueh et al (1997)[13](#jah31280-bib-0013){ref-type="ref"}     \>50      26    ---                Clinically indicated                                       Simultaneous                      ---                      L (PCWP, from graph)             ---                                                                                         E/A \<1                                                                        0                          ---   ---   ---
  Nagueh et al (1998)[14](#jah31280-bib-0014){ref-type="ref"}     \>45      49    ---                ICU or cath lab                                            Simultaneous                      L (PCWP)                 L (PCWP, from graph)             ---                                                                                         LVEF not ≥50%, sinus tachycardia \>100 bpm                                     ---                        ---   ---   ---
  Poerner et al (2003)[17](#jah31280-bib-0017){ref-type="ref"}    ≥55       85    60±10              Angina/positive exercise test                              3±2.5 h                           L, S, M (LVEDP, Pre‐A)   ---                              ---                                                                                         E/A \>0.9                                                                      ---                        ---   ---   ---
  Arques et al (2005)[21](#jah31280-bib-0021){ref-type="ref"}     \>50      38    76±8               Clinically indicated                                       Not reported                      ---                      L (HF, limited data)                                                                                                         ASE guidelines cutoff data not available                                       47                         0     100   39
  Bruch et al (2005)[22](#jah31280-bib-0022){ref-type="ref"}      \>45      28    68±10              Congestive HF; NYHA 2.4±0.4                                ≤4 h                              M (LVEDP, PCWP)          M (LVEDP, from text)             ---                                                                                         LVEF not ≥50%                                                                  100                        50    75    ---
  Hadano et al (2005)[23](#jah31280-bib-0023){ref-type="ref"}     \>50      65    66±9               Clinically indicated                                       ≤3 h                              ---                      L (LVEDP, from graph)            ---                                                                                         Repetitive analysis of same study                                              ---                        28    ---   ---
  Weber et al (2006)[25](#jah31280-bib-0025){ref-type="ref"}      \>50      126   59±9               Coronary angiography                                       Not reported                      ---                      ---                              S (DD/HF, limited data)                                                                     ASE guidelines cutoff data not available                                       35                         49    58    17
  Kasner et al (2007)[26](#jah31280-bib-0026){ref-type="ref"}     \>50      55    ---                43 exercise dyspnea/12 chest pain                          3 to 5 h                          ---                      ---                              L (HF, limited data)                                                                        ASE guidelines cutoff data not available                                       78                         0     62    9
  Min et al (2007)[27](#jah31280-bib-0027){ref-type="ref"}        ≥50       55    59±10              Clinically indicated                                       Simultaneous                      S (LVEDP)                S (LVEDP, from graph)            ---                                                                                         8\< E/è \<15                                                                   ---                        56    46    31
  Poerner et al (2007)[28](#jah31280-bib-0028){ref-type="ref"}    67±10     176   65±10              Coronary angiography                                       1±2.5 h                           ---                      L (LVEDP, from text/graphs)      ---                                                                                         Assumption: LVEF \>40%                                                         ---                        70    63    25
  Dokanish et al (2008)[30](#jah31280-bib-0030){ref-type="ref"}   \>50      32    ---                Dyspnea                                                    Sequential                        ---                      M (Pre‐A, limited data)          ---                                                                                         ASE guidelines cutoff data not available                                       ---                        ---   ---   ---
  Ng et al (2008)[31](#jah31280-bib-0031){ref-type="ref"}         61±5.6    20    ---                Clinically indicated                                       Sequential                        ---                      M (LVEDP, limited data)          ---                                                                                         AUC ROC only                                                                   ---                        ---   ---   ---
  Dokanish et al (2010)[34](#jah31280-bib-0034){ref-type="ref"}   ≥50       122   55±9               Coronary angiography                                       Sequential                        ---                      M (Pre‐A, from graph)            ---                                                                                         Repetitive analysis of another study[22](#jah31280-bib-0022){ref-type="ref"}   ---                        65    88    55
  Jaubert et al (2010)[36](#jah31280-bib-0036){ref-type="ref"}    \>45      59    64±12              Clinically indicated                                       Same morning                      ---                      L (LVEDP, from text)             ---                                                                                         LVEF not ≥50%                                                                  ---                        49    58    36
  Kasner et al (2010)[37](#jah31280-bib-0037){ref-type="ref"}     \>60      33    ---                21 exercise dyspnea/12 chest pain                          Simultaneous                      ---                      ---                              L (HF, limited data)                                                                        AUC ROC only                                                                   64                         0     61    9
  Penicka et al (2010)[38](#jah31280-bib-0038){ref-type="ref"}    \>50      30    67±9               Chronic NYHA II/III dyspnea                                Simultaneous                      ---                      L, S, M (LVEDP, from text)       ---                                                                                         Uncertainty with10% patients[c](#jah31280-note-0009){ref-type="fn"}            67                         0     70    27
  Hsiao et al (2011)[40](#jah31280-bib-0040){ref-type="ref"}      \>50      376   69±13              Coronary angiography, HF survey                            Sequential                        ---                      L, S, M (Pre‐A, limited data)    ---                                                                                         ASE guidelines cutoff data not available                                       ---                        100   72    47
  Kasner et al (2011)[41](#jah31280-bib-0041){ref-type="ref"}     \>50      180   ---                107 exercise dyspnea/73 chest pain                         Simultaneous                      ---                      ---                              L (HF, limited data)                                                                        AUC ROC only                                                                   59                         0     43    8
  Maeder et al (2011)[42](#jah31280-bib-0042){ref-type="ref"}     \>50      36    56±17              11 PAH/15 HF/10 healthy volunteers and atypical patients   Sequential                        ---                      L, S, M (PCWP, limited data)     ---                                                                                         AUC ROC only                                                                   42                         ---   ---   ---
  Yesildag et al (2011)[44](#jah31280-bib-0044){ref-type="ref"}   62±7      29    53±10              Clinically indicated                                       Same day                          L, S (LVEDP)             ---                              ---                                                                                         Assumption: LVEF \>40%                                                         ---                        ---   ---   ---
  Hsiao et al (2012)[45](#jah31280-bib-0045){ref-type="ref"}      \>50      376   ---                Clinically indicated                                       Sequential                        ---                      M (Pre‐A, limited data)          ---                                                                                         ASE guidelines cutoff data not available                                       ---                        ---   ---   ---
  Arques, 2013[47](#jah31280-bib-0047){ref-type="ref"}            ≥50       36    66±10              Clinically indicated                                       Same morning                      ---                      L (LVEDP, from text)             ---                                                                                         ASE guidelines cutoff data not available                                       ---                        53    67    42
  Manouras et al (2013)[48](#jah31280-bib-0048){ref-type="ref"}   ≥40       65    66±9               Coronary angiography                                       Simultaneous                      L, S, M (LVEDP, Pre‐A)   L, M (LVEDP, Pre‐A, from text)   ---                                                                                         LVEF not ≥50%                                                                  ---                        0     45    42
  Weber et al (2013)[49](#jah31280-bib-0049){ref-type="ref"}      \>50      359   64±9               Coronary angiography                                       Not reported                      ---                      ---                              S, M (HF, limited data)                                                                     AUC ROC only                                                                   20                         49    83    24

Empty cells are the result of no available data. 2×2 indicates set of true‐positive, false‐positive, false‐negative, and true‐negative values for recommended by American Society of Echocardiography E/è cutoffs; CAD, coronary artery disease; cath lab, catheterization laboratory; CCU, critical care unit; DD, diastolic dysfunction; DM, diabetes mellitus; E/A, the ratio of the early (E) to late (A) ventricular filling velocities; HF, heart failure (clinical diagnosis); HTN, hypertension; ICU, intensive care unit; L, S, and M, lateral, septal, and mean E/è; LVEDP, left ventricular end‐diastolic pressure; LVEF, left ventricular ejection fraction; LVFP, left ventricular filling pressure; LVMDP, left ventricular mean diastolic pressure; N, number of patients; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PCWP, pulmonary capillary wedge pressure; pEF, preserved ejection fraction; Pre‐A, left ventricular pre--A wave diastolic pressure; ROC AUC, area under receiver operating characteristic curve.

For supplemental analysis, we included studies that either used a lower LVEF threshold to identify preserved LV systolic function (ie, LVEF ≥40% or 45%) or had no criteria for normal LVEF but the mean and standard deviation for LVEF of the study satisfied the condition that mean minus 2 SDs ≥40%. For a normal distribution, the latter condition assumes that about 98% of participants have LVEF ≥40%. This allowed for inclusion of all clinically relevant studies for secondary analysis since LVEF between 40% to 50% is sometimes used to indicate preserved LVEF.

Clinical DD/HFpEF was described in studies based on composite of clinical signs and symptoms of HF with invasive parameters of DD with preserved LVEF. Some of these studies also included BNP (brain natriuretic peptide) or NT‐proBNP (N‐terminal of the prohormone brain natriuretic peptide) biochemical levels in composite reference definition. No uniform definition was used for clinical diagnosis of DD/HFpEF across these studies.

Elevated LVFP group included 3 patients who had LVEDP \>16 mm Hg only after hemodynamic interventions.

We excluded studies where the cohort of pEF patients could include ≥10% of patients with moderate to severe valvular heart disease, hypertrophic or restrictive cardiomyopathy, age \<18 years, congenital heart disease, acute coronary syndromes, septic shock, cardiac transplant, atrial fibrillation, or \<10 participants. We did not exclude studies that did not explicitly describe the abovementioned conditions in either inclusion/exclusion criteria or baseline patient characteristics. We excluded studies if study reference tests were based only on noninvasive criteria of DD/HFpEF.

Quality Assessment and Data Extraction {#jah31280-sec-0008}
--------------------------------------

The selected studies were analyzed for the risk of bias and applicability concerns by consensus of 2 investigators (O.F.S. and H.G.). We used the Quality Assessment of Diagnostic Accuracy Studies questionnaire[9](#jah31280-bib-0009){ref-type="ref"} optimized to our study questions (Appendix S3). Risk of bias was tested for 4 domains: patient selection, index test, reference test, and flow and timing. Applicability was tested for patient selection, index, and reference test domains (Table [3](#jah31280-tbl-0003){ref-type="table-wrap"}). The questionnaire was expanded to incorporate risks of differential verification on index test accuracy in clinical study (Appendix S3). Index tests were E/è~lateral~, E/è~septal~, or E/è~mean~. Reference tests were invasive LVFP measurements of LVEDP, LV mean diastolic pressure (LVMDP), LV pre‐A diastolic pressure (Pre‐A), PCWP, or invasively proven DD/HFpEF (Tables [1](#jah31280-tbl-0001){ref-type="table-wrap"} and [2](#jah31280-tbl-0002){ref-type="table-wrap"}).

###### 

Summary of QUADAS‐2 Assessment of Selected Studies

  Study (Reference)                                                               Risk of Bias   Applicability Concerns                                           
  ------------------------------------------------------------------------------- -------------- ------------------------ --------- --------- --------- --------- ---------
  Nagueh et al (1997)[13](#jah31280-bib-0013){ref-type="ref"}                     Unclear        Low                      Low       Low       Low       Low       Low
  Nagueh et al (1998)[14](#jah31280-bib-0014){ref-type="ref"}                     Low            Low                      Low       Low       High      Low       Low
  Ommen et al (2000)[15](#jah31280-bib-0015){ref-type="ref"}                      Low            Low                      Low       Low       Low       Low       Low
  Gonzalez‐Vilchez et al (2002)[16](#jah31280-bib-0016){ref-type="ref"}           High           Low                      Low       Low       High      Low       Low
  Poerner et al (2003)[17](#jah31280-bib-0017){ref-type="ref"}                    Low            Low                      Low       Low       Low       High      Low
  Rivas‐Gotz et al (2003)[18](#jah31280-bib-0018){ref-type="ref"}                 Low            Low                      Low       Low       Unclear   Unclear   Low
  Dokanish et al (2004)[19](#jah31280-bib-0019){ref-type="ref"}                   Unclear        Low                      Low       Low       High      Unclear   Low
  Mansencal et al (2004)[20](#jah31280-bib-0020){ref-type="ref"}                  Low            Low                      Low       Low       High      Unclear   Unclear
  Arques et al (2005)[21](#jah31280-bib-0021){ref-type="ref"}                     High           Low                      High      High      High      Low       Low
  Bruch et al (2005)[22](#jah31280-bib-0022){ref-type="ref"}                      Unclear        Unclear                  Unclear   Low       High      Low       Low
  Hadano et al (2005)[23](#jah31280-bib-0023){ref-type="ref"}                     Unclear        Unclear                  Low       Low       Low       Unclear   Low
  Kidawa et al (2005)[24](#jah31280-bib-0024){ref-type="ref"}                     Low            Low                      Low       Low       Low       Unclear   Low
  Weber et al (2006)[25](#jah31280-bib-0025){ref-type="ref"}                      Low            Low                      Unclear   Unclear   High      Unclear   Low
  Kasner et al (2007)[26](#jah31280-bib-0026){ref-type="ref"}                     High           Low                      Low       Low       High      Low       Low
  Min et al (2007)[27](#jah31280-bib-0027){ref-type="ref"}                        Low            Low                      Low       Low       Low       Unclear   Low
  Poerner et al (2007)[28](#jah31280-bib-0028){ref-type="ref"}                    Low            Low                      Low       Low       Low       High      Low
  Wang et al (2007)[29](#jah31280-bib-0029){ref-type="ref"}                       Unclear        Low                      Low       Low       Unclear   Low       Low
  Dokanish et al (2008)[30](#jah31280-bib-0030){ref-type="ref"}                   Low            Low                      Low       Low       Unclear   Unclear   Low
  Ng et al (2008)[31](#jah31280-bib-0031){ref-type="ref"}                         Unclear        Low                      High      Low       Unclear   Low       Low
  Rudko et al (2008)[32](#jah31280-bib-0032){ref-type="ref"}                      Low            Low                      Low       Low       High      Unclear   Low
  Dini et al (2010)[33](#jah31280-bib-0033){ref-type="ref"}                       Unclear        Low                      Unclear   Low       Low       Unclear   Low
  Dokanish et al (2010)[34](#jah31280-bib-0034){ref-type="ref"}                   Low            Low                      Unclear   Low       Unclear   Unclear   Low
  Dokanish et al (2010)[35](#jah31280-bib-0035){ref-type="ref"}                   Low            Low                      Unclear   Low       Unclear   Unclear   Low
  Jaubert et al (2010)[36](#jah31280-bib-0036){ref-type="ref"}                    Low            Low                      Low       Low       Low       Low       Low
  Kasner et al (2010)[37](#jah31280-bib-0037){ref-type="ref"}                     High           Low                      Low       Low       High      Unclear   Low
  Penicka et al (2010)[38](#jah31280-bib-0038){ref-type="ref"}                    High           Unclear                  Unclear   Low       Unclear   Unclear   Low
  Bhella et al (2011)[39](#jah31280-bib-0039){ref-type="ref"}                     High           Low                      Low       Low       High      Unclear   Low
  Hsiao et al (2011)[40](#jah31280-bib-0040){ref-type="ref"}                      Unclear        Low                      Low       Low       High      Low       Low
  Kasner et al (2011)[41](#jah31280-bib-0041){ref-type="ref"}                     Unclear        Low                      Low       Low       Unclear   Low       Low
  Maeder et al (2011)[42](#jah31280-bib-0042){ref-type="ref"}                     Low            Low                      Low       Low       Low       Unclear   Low
  Özer et al (2011)[43](#jah31280-bib-0043){ref-type="ref"}                       Low            Low                      Low       Low       High      Low       Low
  Yesildag et al (2011)[44](#jah31280-bib-0044){ref-type="ref"}                   Unclear        Low                      Low       Low       Low       Unclear   Low
  Hsiao et al (2012)[45](#jah31280-bib-0045){ref-type="ref"}                      Unclear        Low                      Low       Low       Unclear   Low       Low
  Previtali et al (2012)[46](#jah31280-bib-0046){ref-type="ref"}                  Unclear        Low                      Low       Low       Low       Unclear   Low
  Arques, 2013[47](#jah31280-bib-0047){ref-type="ref"}                            Unclear        Low                      Low       Low       Unclear   Unclear   Low
  Manouras et al (2013)[48](#jah31280-bib-0048){ref-type="ref"}                   Low            Low                      Low       Low       Unclear   Unclear   Low
  Weber et al (2013)[49](#jah31280-bib-0049){ref-type="ref"}                      Low            Unclear                  Unclear   Unclear   Unclear   Unclear   Low
  Hajahmadi Poorrafsanjani et al (2014)[50](#jah31280-bib-0050){ref-type="ref"}   Low            Low                      Low       Low       Unclear   Unclear   Low
  Tatsumi et al (2014)[51](#jah31280-bib-0051){ref-type="ref"}                    Unclear        Low                      Low       Unclear   Unclear   Unclear   Low

QUADAS‐2 questionnaire optimized to our study questions is presented below. QUADAS‐2 indicates Quality Assessment of Diagnostic Accuracy Studies 2.

Numerical data were extracted by O.F.S. and confirmed by C.G.S. or H.G. A set was obtained of true‐positive, false‐positive, false‐negative, and true‐negative (2×2) values for E/è cutoffs to identify or exclude elevated LVFP or DD/HFpEF. In some studies (specified in Results), 2×2 values were manually extracted from the scatter plots (LVFP versus E/è). Linear regression coefficient for E/è--LVFP relationship was obtained if provided in the study text. In addition, data for LV relaxation time constant (τ) and LV stiffness parameters invasive reference standards were obtained if provided.

Data Synthesis and Analysis {#jah31280-sec-0009}
---------------------------

### E/è--LVFP linear regression {#jah31280-sec-0010}

To summarize the relationship between E/è~lateral~, E/è~septal~, or E/è~mean~ and invasive LVFP (LVEDP, PCWP, LVMDP, or Pre‐A, separately), we calculated the weighted summary linear regression coefficient (*r*) by using the continuous random‐effects model.[10](#jah31280-bib-0010){ref-type="ref"} We chose a random‐effects model because we anticipate variation in the effect size among our studies because of substantial heterogeneity in the design and patient population among the individual studies. The model can be presented as Y~i~=μ+ε~i~+ξ~i~, where ε~i~≈N (0, ν~i~ ^2^) and ξ~i~≈N (0, τ^2^). Y~i~ is effect size (linear regression coefficient), μ is the mean of the underlying effect size distribution, ν~i~ is the sampling variance for the effect size (within study variance), and τ^2^ is the variance of overall effect size distribution (study‐to‐study variance). We used the DerSimonian--Laird method for calculating τ^2^. In some cases, when τ^2^=0, the summary effect size was estimated in a fixed‐effect model by using the inverse‐variance method. In the latter method, the summary effect Y is computed as a weighted sum of individual study effects, where the weights are proportional to the inverse of the within‐study variance. Initially, only primary data (Table [1](#jah31280-tbl-0001){ref-type="table-wrap"}) were analyzed. Then, the secondary analysis was performed with and without supplemental data (Table [2](#jah31280-tbl-0002){ref-type="table-wrap"}) to evaluate the impact of heterogeneous study designs on the effect size. Possible confounding factors such as the timing of echocardiographic and invasive measurements (simultaneous versus not simultaneous) and the prevalence of specific patient population/disease were independently considered in subgroup analysis. Heterogeneity among the studies was estimated with use of the *I* ^2^ statistic.

### Diagnostic accuracy of ASE‐recommended E/è cutoffs {#jah31280-sec-0011}

For evaluation of diagnostic accuracy of E/è to identify either elevated or normal LVFP, we relied on the ASE‐recommended E/è cutoff values.[4](#jah31280-bib-0004){ref-type="ref"} Specifically, E/è~lateral~ \>12, E/è~mean~ \>13, or E/è~septal~ \>15 indicates elevated LVFP, whereas E/è \<8 (any location) indicates normal LVFP. We also used ASE‐recommended threshold values for quantifying elevated LVFP that are LVEDP \>16 mm Hg and PCWP \>12 mm Hg.[4](#jah31280-bib-0004){ref-type="ref"} For LVMDP and Pre‐A, values \>12 and \>15 mm Hg, respectively, were used because these values were used in individual studies. Sensitivity and specificity with 95% CI for individual studies were computed based on a diagnostic random‐effects model.[10](#jah31280-bib-0010){ref-type="ref"} To obtain summary points that take into account within‐study variability and between‐study variability (heterogeneity), we performed hierarchical summary receiver operating characteristic analysis by using the Rutter and Gatsonis model.[11](#jah31280-bib-0011){ref-type="ref"} Estimation was carried out via a Bayesian approach, implemented via a Gibbs sampler. Summary point from the hierarchical summary receiver operating characteristic analysis was then used to calculate positive likelihood ratio (LR^+^). The summary sensitivity and specificity values were also used to calculate the relationship of positive predictive value (PPV) with prevalence for elevated or normal LVFP ranging from 5% to 95%, which was compiled and graphed by using MATLAB R2013b. Separate analyses were performed for E/è~lateral~, E/è~mean~, and E/è~septal~.

For the primary analysis, we pooled all invasive reference methods for evaluating LVFP (ie, LVEDP, PCWP, Pre‐A, LVMDP) because the number of "primary data" studies (Table [1](#jah31280-tbl-0001){ref-type="table-wrap"}) was limited. This allowed a pragmatic statistical analysis with direct clinical applicability. Then, we performed the secondary hierarchical summary receiver operating characteristic analysis with and without supplemental data (Table [2](#jah31280-tbl-0002){ref-type="table-wrap"}) to assess diagnostic accuracy for LVEDP, PCWP, and Pre‐A separately (if ≥3 studies were available) and to assess the effects of the confounding factors mentioned above.

### Diagnostic accuracy of optimal E/è cutoffs {#jah31280-sec-0012}

Descriptive summary for optimal E/è cutoff values from the receiver operating characteristic (ROC; which are different across the studies) to identify elevated/normal LVFP is also provided as part of secondary analysis. In studies that did not provide the optimal cutoff, we created the ROC curve and identified the optimal cutoff as the point on the ROC curve closest to (0,1 on *x*‐*y* coordinate).

### Statistical software {#jah31280-sec-0013}

OpenMetaAnalyst software[12](#jah31280-bib-0012){ref-type="ref"} for Windows (64‐bit version; Microsoft) was used for statistical analysis including graphic presentations of forest plots of sensitivity and specificity and hierarchical summary ROC curves.

Results {#jah31280-sec-0014}
=======

Summary of the study selection is presented in Figure [1](#jah31280-fig-0001){ref-type="fig"}. Amongst 21 013 unique citations, we reviewed full text of 314 studies; 275 studies (listed in Appendix S4) were excluded with reasons, and 39 studies[13](#jah31280-bib-0013){ref-type="ref"}, [14](#jah31280-bib-0014){ref-type="ref"}, [15](#jah31280-bib-0015){ref-type="ref"}, [16](#jah31280-bib-0016){ref-type="ref"}, [17](#jah31280-bib-0017){ref-type="ref"}, [18](#jah31280-bib-0018){ref-type="ref"}, [19](#jah31280-bib-0019){ref-type="ref"}, [20](#jah31280-bib-0020){ref-type="ref"}, [21](#jah31280-bib-0021){ref-type="ref"}, [22](#jah31280-bib-0022){ref-type="ref"}, [23](#jah31280-bib-0023){ref-type="ref"}, [24](#jah31280-bib-0024){ref-type="ref"}, [25](#jah31280-bib-0025){ref-type="ref"}, [26](#jah31280-bib-0026){ref-type="ref"}, [27](#jah31280-bib-0027){ref-type="ref"}, [28](#jah31280-bib-0028){ref-type="ref"}, [29](#jah31280-bib-0029){ref-type="ref"}, [30](#jah31280-bib-0030){ref-type="ref"}, [31](#jah31280-bib-0031){ref-type="ref"}, [32](#jah31280-bib-0032){ref-type="ref"}, [33](#jah31280-bib-0033){ref-type="ref"}, [34](#jah31280-bib-0034){ref-type="ref"}, [35](#jah31280-bib-0035){ref-type="ref"}, [36](#jah31280-bib-0036){ref-type="ref"}, [37](#jah31280-bib-0037){ref-type="ref"}, [38](#jah31280-bib-0038){ref-type="ref"}, [39](#jah31280-bib-0039){ref-type="ref"}, [40](#jah31280-bib-0040){ref-type="ref"}, [41](#jah31280-bib-0041){ref-type="ref"}, [42](#jah31280-bib-0042){ref-type="ref"}, [43](#jah31280-bib-0043){ref-type="ref"}, [44](#jah31280-bib-0044){ref-type="ref"}, [45](#jah31280-bib-0045){ref-type="ref"}, [46](#jah31280-bib-0046){ref-type="ref"}, [47](#jah31280-bib-0047){ref-type="ref"}, [48](#jah31280-bib-0048){ref-type="ref"}, [49](#jah31280-bib-0049){ref-type="ref"}, [50](#jah31280-bib-0050){ref-type="ref"}, [51](#jah31280-bib-0051){ref-type="ref"} met our inclusion criteria. Data for the primary analysis were available in 24 studies (Table [1](#jah31280-tbl-0001){ref-type="table-wrap"}).

![Summary of the literature search. Primary analysis studies include data for patients with LVEF ≥50%. Supplemental analysis studies include data either for patients with LVEF ≥40% and/or with preselected echocardiographic indices (eg, the ratio of the early (E) to late (A) ventricular filling velocities (E/A) \<0.9). DD/HFpEF represents invasively proven DD/HFpEF (i.e. clinical diagnosis of DD/HFpEF based on clinical sign and symptoms with evidence of elevated LVFP or impaired LV relaxation/chamber stiffness with or without additional biochemical markers and/or other ancillary tests). DD indicates diastolic dysfunction; HF, heart failure; LVEF, left ventricular ejection fraction; LVFP, left ventricular filling pressure; pEF, preserved ejection fraction.](JAH3-5-e002530-g001){#jah31280-fig-0001}

Quality Assessment {#jah31280-sec-0015}
------------------

On Quality Assessment of Diagnostic Accuracy Studies analysis for assessment of bias, we found that patient selection domain had high or unclear risk in a substantial number of studies (50% among primary studies, 51% for all selected studies) (Table [3](#jah31280-tbl-0003){ref-type="table-wrap"} and Figure [2](#jah31280-fig-0002){ref-type="fig"}). The major reasons for such risk were convenience sampling, lack of comprehensive exclusion/inclusion criteria, and/or recruiting patients with specific symptoms or disease. Similarly for evaluating applicability, patient selection domain had a high or unclear risk in a majority of studies (83% among primary studies, 82% for all selected studies). Important reasons for this were lack of patient characteristics (diagnosis, comorbidities), selection of inappropriate control groups, and high (up to 100%) prevalence of certain disease phenotypes (eg, all coronary artery disease or HFpEF). For reference and index test, interobserver and intraobserver variabilities were not described in a substantial number of studies (67% among primary studies, 51% for all selected studies). Overall, only 2 studies (one for primary analysis) had low risk in all aspects of Quality Assessment of Diagnostic Accuracy Studies questionnaire.

![Summary of quality assessment analysis (Quality Assessment of Diagnostic Accuracy Studies \[QUADAS 2\]). A, QUADAS 2 bar charts for primary analysis studies (n=24). B, QUADAS 2 bar charts for all selected studies (n=39).](JAH3-5-e002530-g002){#jah31280-fig-0002}

Correlation Effect Size for Estimating LVFP {#jah31280-sec-0016}
-------------------------------------------

### Primary data analysis {#jah31280-sec-0017}

Summary estimates of linear regression coefficient (*r*) with 95% CIs for E/è and LVFP for primary studies are shown in Table [4](#jah31280-tbl-0004){ref-type="table-wrap"}. All the summary point estimates are \<0.5, revealing poor to mediocre correlation.

###### 

Correlation (*r*) Between Invasive Measurements of LVFP and E/è

  E/è                                                                                           LVFP, mm Hg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  --------------------------------------------------------------------------------------------- --------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
  All primary studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Lateral                                                                                       *r* (95% CI) Studies Heterogeneity Total patients   0.44 (0.30--0.57) (N=8[23](#jah31280-bib-0023){ref-type="ref"}, [24](#jah31280-bib-0024){ref-type="ref"}, [26](#jah31280-bib-0026){ref-type="ref"}, [37](#jah31280-bib-0037){ref-type="ref"}, [43](#jah31280-bib-0043){ref-type="ref"}, [46](#jah31280-bib-0046){ref-type="ref"}, [48](#jah31280-bib-0048){ref-type="ref"}, [50](#jah31280-bib-0050){ref-type="ref"}); (*I* ^2^=61, *P*=0.013) (n=419)   0.46 (0.19-- 0.73) (N=4[16](#jah31280-bib-0016){ref-type="ref"}, [18](#jah31280-bib-0018){ref-type="ref"}, [23](#jah31280-bib-0023){ref-type="ref"}, [42](#jah31280-bib-0042){ref-type="ref"}); (*I* ^2^=79, *P*=0.003 (n=188)   0.23 (0.10--0.36) (N=4[20](#jah31280-bib-0020){ref-type="ref"}, [40](#jah31280-bib-0040){ref-type="ref"}, [46](#jah31280-bib-0046){ref-type="ref"}, [48](#jah31280-bib-0048){ref-type="ref"}); (*I* ^2^=0, *P*=0.56) (n=215)                                                0.4 (N=1[15](#jah31280-bib-0015){ref-type="ref"}); N/A (n=64)
  Septal                                                                                        *r* (95% CI) Studies Heterogeneity Total patients   0.28 (0.08--0.49) (N=4[24](#jah31280-bib-0024){ref-type="ref"}, [43](#jah31280-bib-0043){ref-type="ref"}, [46](#jah31280-bib-0046){ref-type="ref"}, [48](#jah31280-bib-0048){ref-type="ref"}); (*I* ^2^=54, *P*=0.09) (n=190)                                                                                                                                                                            0.48 (0.26--0.70) (N=3[18](#jah31280-bib-0018){ref-type="ref"}, [42](#jah31280-bib-0042){ref-type="ref"}, [51](#jah31280-bib-0051){ref-type="ref"}) (*I* ^2^=42, *P*=0.18) (n=113)                                               0.24 (0.09--0.40) (N=3[40](#jah31280-bib-0040){ref-type="ref"}, [46](#jah31280-bib-0046){ref-type="ref"}, [48](#jah31280-bib-0048){ref-type="ref"}); (*I* ^2^=15, *P*=0.31) (n=195)                                                                                         0.47 (0.30--0.64) (N=2[15](#jah31280-bib-0015){ref-type="ref"}, [32](#jah31280-bib-0032){ref-type="ref"}); (*I* ^2^=0, *P*=1.00) (n=103)
  Mean                                                                                          *r* (95% CI) Studies Heterogeneity Total patients   0.38 (0.11--0.65) (N=4[35](#jah31280-bib-0035){ref-type="ref"}, [43](#jah31280-bib-0043){ref-type="ref"}, [46](#jah31280-bib-0046){ref-type="ref"}, [48](#jah31280-bib-0048){ref-type="ref"}); (*I* ^2^=81, *P*=0.001) (n=262)                                                                                                                                                                           0.49 (0.25--0.73) (N=4[18](#jah31280-bib-0018){ref-type="ref"}, [29](#jah31280-bib-0029){ref-type="ref"}, [39](#jah31280-bib-0039){ref-type="ref"}, [42](#jah31280-bib-0042){ref-type="ref"}); (*I* ^2^=51, *P*=0.10) (n=122)    0.31 (0.07--0.55) (N=5[30](#jah31280-bib-0030){ref-type="ref"}, [34](#jah31280-bib-0034){ref-type="ref"}, [40](#jah31280-bib-0040){ref-type="ref"}, [46](#jah31280-bib-0046){ref-type="ref"}, [48](#jah31280-bib-0048){ref-type="ref"}); (*I* ^2^=82, *P*\<0.001) (n=349)   0.45 (N=1[15](#jah31280-bib-0015){ref-type="ref"}); N/A (n=64)
  Primary studies with simultaneous measurements of echocardiographic and invasive parameters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Lateral                                                                                       *r* (95% CI) Studies Heterogeneity Total patients   0.51 (0.36--0.67) (N=3[24](#jah31280-bib-0024){ref-type="ref"}, [26](#jah31280-bib-0026){ref-type="ref"}, [48](#jah31280-bib-0048){ref-type="ref"}); (*I* ^2^=0, *P*=0.40) (n=143)                                                                                                                                                                                                                       0.7 (0.51--0.89) (N=1[18](#jah31280-bib-0018){ref-type="ref"}); N/A (n=55)                                                                                                                                                       0.4 (0.19--0.61) (N=1[48](#jah31280-bib-0048){ref-type="ref"}); N/A (n=38)                                                                                                                                                                                                  0.4 (N=1[15](#jah31280-bib-0015){ref-type="ref"}); N/A (n=64)
  Septal                                                                                        *r* (95% CI) Studies Heterogeneity Total patients   0.18 (−0.08 to 0.43) (N=2[24](#jah31280-bib-0024){ref-type="ref"}, [48](#jah31280-bib-0048){ref-type="ref"}); (*I* ^2^=31, *P*=0.23) (n=88)                                                                                                                                                                                                                                                              0.55 (0.32--0.78) (N=1[18](#jah31280-bib-0018){ref-type="ref"}) N/A (n=55)                                                                                                                                                       0.02 (−0.30 to 0.34) (N=1[48](#jah31280-bib-0048){ref-type="ref"}); N/A (n=38)                                                                                                                                                                                              0.47 (0.30--0.64) (N=2[15](#jah31280-bib-0015){ref-type="ref"}, [32](#jah31280-bib-0032){ref-type="ref"}); (*I* ^2^=0, *P*=1.00) (n=103)
  Mean                                                                                          *r* (95% CI) Studies Heterogeneity Total patients   0.18 (−0.14 to 0.50) (N=1[48](#jah31280-bib-0048){ref-type="ref"}); N/A (n=38)                                                                                                                                                                                                                                                                                                                           0.6 (0.42--0.78) (N=3[18](#jah31280-bib-0018){ref-type="ref"}, [29](#jah31280-bib-0029){ref-type="ref"}, [39](#jah31280-bib-0039){ref-type="ref"}); (*I* ^2^=0, *P*=0.91) (n=86)                                                 0.21 (−0.11 to 0.53) (N=1[48](#jah31280-bib-0048){ref-type="ref"}); N/A (n=38)                                                                                                                                                                                              0.45 (N=1[15](#jah31280-bib-0015){ref-type="ref"}); N/A (n=64)

Heterogeneity among the studies was estimated by using the *I* ^2^ statistic, and the corresponding *P* values are provided. N indicates number of studies; n, total patients N/A, not applicable.

### Secondary data analysis {#jah31280-sec-0018}

In Table [4](#jah31280-tbl-0004){ref-type="table-wrap"}, we also present summary estimates of linear regression coefficients in studies where invasive and echocardiographic measurements were performed simultaneously. As apparent, in only a few studies were simultaneous measurements performed for each individual LVFP parameter. The results remain consistent with the primary analysis with no obvious trends. While in some studies the *r* estimates were somewhat higher, in others they were lower compared with the entire primary combined data set (Table [4](#jah31280-tbl-0004){ref-type="table-wrap"}). Increased *r* values were mainly observed in studies that measured PCWP. However, these data cannot be applied to the general patient cohort because 2 of the 3 studies were conducted in the intensive care unit setting.[18](#jah31280-bib-0018){ref-type="ref"}, [29](#jah31280-bib-0029){ref-type="ref"} These 2 studies did not provide detailed patient characteristics. The third study had an extremely small sample size.[39](#jah31280-bib-0039){ref-type="ref"} On secondary analysis with an additional 6 studies from Table [2](#jah31280-tbl-0002){ref-type="table-wrap"}, the summary estimates remained similar (Appendix S5). Because of the limited number of studies that specified patient characteristics for the pEF cohort, no conclusive effect of prevalence of HFpEF, coronary artery disease, hypertension, and diabetes mellitus on *r* estimate was found (Appendix S5).

Diagnostic Accuracy of E/è for Identification of Elevated LVFP {#jah31280-sec-0019}
--------------------------------------------------------------

### Primary data analysis {#jah31280-sec-0020}

The summary data for the diagnostic accuracy of E/è to identify elevated LVFP demonstrated wide CIs for sensitivity and specificity (Figure [3](#jah31280-fig-0003){ref-type="fig"}A, [3](#jah31280-fig-0003){ref-type="fig"}D, and [3](#jah31280-fig-0003){ref-type="fig"}G). There was significant heterogeneity for E/è~lateral~ specificity and E/è~mean~ sensitivity measurements. The summary sensitivity and specificity for E/è~lateral~ (n=6), E/è~mean~ (n=6), and E/è~septal~ (n=4) were 30% and 92%, 37% and 91%, and 24% and 98%, respectively (Figure [3](#jah31280-fig-0003){ref-type="fig"}B, [3](#jah31280-fig-0003){ref-type="fig"}E, and [3](#jah31280-fig-0003){ref-type="fig"}H). Only E/è~septal~ had sufficiently high LR^+^ (slightly above 10) in identifying elevated LVFP, whereas LR^+^ for E/è~lateral~ and E/è~mean~ was low (3.8 and 4.1, respectively).

![Diagnostic accuracy of E/è recommended by the American Society of Echocardiography (ASE) to identify elevated left ventricular filling pressure (LVFP). A through C, Analysis for E/è~lateral~ (\>12). A, Individual studies (reference number as listed in the main text is indicated in brackets) with corresponding LVFP measurements, sample size, elevated LVFP prevalence, diagnostic 2×2 data (true positive \[TP\], false positive \[FP\], false negative \[FN\], true negative \[TN\]), and corresponding values of sensitivity (Sens.) and specificity (Spec.) with 95% CI are described. Summary heterogeneity is described by *I* ^2^ statistic. B, The Rutter and Gatsonis[11](#jah31280-bib-0011){ref-type="ref"} hierarchical summary receiver operating characteristic (HSROC) analysis for recommended E/è cutoff to identify elevated LVFP is depicted. Summary sensitivity, summary specificity with 95% CI, and corresponding positive likelihood ratio (LR+) are depicted. C, Positive predictive value (PPV)--prevalence relationship for E/è to identify elevated LVFP using summary sensitivity and specificity HSROC points. Prevalence of elevated LVFP corresponding to 50% PPV for E/è is highlighted. \*TP,FP,FN,TN values were extracted from the graphical data representation of LVFP vs E/è in study results; for such study, column presenting patient number (N) include 2 numbers: first number is actual counted patients in the plot, and second number is total patients in the study group. D through F, Analysis for E/è~mean~ (\>13). G through I, Analysis for E/è~septal~ (\>15). Other description is same as for A through C.](JAH3-5-e002530-g003){#jah31280-fig-0003}

### Secondary data analysis {#jah31280-sec-0021}

Because of a limited number of studies and limited data on patient characteristics, we could not identify the reasons for heterogeneity found for sensitivity, specificity, and LR^+^ estimates in individual studies (Appendix S6). Among studies for E/è~septal~ assessment, the highest individual LR^+^ was in Ommen et al\'s (2000) study[15](#jah31280-bib-0015){ref-type="ref"} (LR^+^=24), whereas LR^+^ values from all other E/è~septal~ studies were \<8. For E/è~septal~, 3 of the 4 studies[15](#jah31280-bib-0015){ref-type="ref"}, [18](#jah31280-bib-0018){ref-type="ref"}, [32](#jah31280-bib-0032){ref-type="ref"} performed simultaneous echocardiography and invasive measurements. Analysis of these 3 studies did not alter our results. For E/è~lateral,~ only 2 of 6 studies,[18](#jah31280-bib-0018){ref-type="ref"}, [24](#jah31280-bib-0024){ref-type="ref"} and for E/è~mean~, only 1 of 6 studies[19](#jah31280-bib-0019){ref-type="ref"} reported simultaneous measurements of echocardiographic and invasive parameters. Secondary analysis with additional studies (identified in the Table [2](#jah31280-tbl-0002){ref-type="table-wrap"}) did not alter summary sensitivity, specificity, or LR^+^ (Appendix S6). Additional secondary subgroup analysis restricted to LVEDP, PCWP, or Pre‐A reference tests individually did not alter the LR^+^ of E/è (Appendix S6). The optimal E/è cutoffs from ROC to identify elevated LVFP in individual studies (Appendix S7) demonstrated a wide range (E/è~lateral~ 6.6--10, E/è~mean~ 8--15, and E/è~septal~ 9--13).

Diagnostic Accuracy of E/è for Identification of Normal LVFP {#jah31280-sec-0022}
------------------------------------------------------------

### Primary data analysis {#jah31280-sec-0023}

For the diagnostic accuracy of E/è to identify normal LVFP, we found significant heterogeneity in either the sensitivity or the specificity estimates among the studies for E/è~lateral~ and E/è~mean~ and not for E/è~septal~ (Figure [4](#jah31280-fig-0004){ref-type="fig"}A, [4](#jah31280-fig-0004){ref-type="fig"}D, and [4](#jah31280-fig-0004){ref-type="fig"}G).The summary sensitivity and specificity for E/è~lateral~ (n=5) were 64% and 73%, respectively; for E/è~mean~ (n=4), they were 36% and 83%; and for E/è~septal~ (n=3), they were 50% and 89%. The corresponding LR^+^ was 2.4, 2.1, and 4.5, respectively (Figure [4](#jah31280-fig-0004){ref-type="fig"}B, [4](#jah31280-fig-0004){ref-type="fig"}E, and [4](#jah31280-fig-0004){ref-type="fig"}H).

![Diagnostic accuracy of E/è recommended by the American Society of Echocardiography to identify normal left ventricular filling pressure (LVFP). A through C, Analysis for E/è~lateral~ (\<8). A, Individual studies (reference number as listed in the main text is indicated in brackets) with corresponding LVFP measurements, sample size, normal LVFP prevalence, diagnostic 2×2 data, and corresponding values of sensitivity and specificity with 95% CIs are described. Summary heterogeneity is described by *I* ^2^ statistic. B, Hierarchical summary receiver operating characteristic (HSROC) analysis for recommended E/è cutoff to identify normal LVFP is depicted. Summary sensitivity, summary specificity with 95% CI, and corresponding positive likelihood ratio (LR+) are depicted. C, Positive predictive value (PPV)--prevalence relationship for E/è to identify normal LVFP using summary sensitivity and specificity HSROC points. Prevalence of normal LVFP corresponding to 50% PPV for E/è is highlighted. \*Same as in Figure [3](#jah31280-fig-0003){ref-type="fig"}. D through F, Analysis for E/è~mean~ (\<8). G through I, Analysis for E/è~septal~ (\<8). Other description is same as for A through C.](JAH3-5-e002530-g004){#jah31280-fig-0004}

### Secondary data analysis {#jah31280-sec-0024}

None of the secondary analyses improved the summary sensitivity and specificity (Appendix S8).

Clinical Context of the Findings Described Earlier {#jah31280-sec-0025}
--------------------------------------------------

We evaluated the relationship of elevated LVFP prevalence (5--95%) and PPV of E/è (Figure [3](#jah31280-fig-0003){ref-type="fig"}C, [3](#jah31280-fig-0003){ref-type="fig"}F, and [3](#jah31280-fig-0003){ref-type="fig"}I). We find that for disease prevalence of ≈≤20%, the PPV to identify elevated LVFP using E/è~lateral~ and E/è~mean~ was \<50% indicating that false positives are greater than the true positives. For E/è~septal~ this occurs for disease prevalence of 10% and below. Similarly we performed prevalence‐PPV relationship analysis to identify normal LVFP (Figure [4](#jah31280-fig-0004){ref-type="fig"}C, [4](#jah31280-fig-0004){ref-type="fig"}F, and [4](#jah31280-fig-0004){ref-type="fig"}I). We find that for normal LVFP prevalence ≤30%, the PPV to identify normal LVFP is \<50% for E/è~lateral~ and E/è~mean~. For E/è~septal~, PPV falls to \<50% for normal LVFP prevalence ≤20%.

Diagnostic Accuracy of E/è for Identification of DD/HFpEF {#jah31280-sec-0026}
---------------------------------------------------------

Only 1 study[38](#jah31280-bib-0038){ref-type="ref"} provided data for creating 2×2 tables for the ASE‐recommended E/è cutoff values. Therefore, we provide descriptive summary (Table [5](#jah31280-tbl-0005){ref-type="table-wrap"}). All studies, except 1,[49](#jah31280-bib-0049){ref-type="ref"} used case‐control design. In Weber et al\'s (2013) study,[49](#jah31280-bib-0049){ref-type="ref"} we find that the area under the ROC curve for the diagnostic accuracy of E/è was lower with mixed patient groups (definite HFpEF, possible HFpEF, and no HFpEF) compared with when patient group with possible HFpEF was removed from the analysis (Table [5](#jah31280-tbl-0005){ref-type="table-wrap"}). Different clinical criteria were used across the studies for diagnosing HFpEF, which limits the use of these data for the purpose of identifying DD/HFpEF by using E/è.

###### 

Identification of HFpEF/LVDD Based on E/è

  Study                                                                        Reference Test to Define HFpEF/DD                                                                                                                     Control Patients                                                                                                                                                          ROC AUC (95% CI)    E/è Cutoff                                      Sensitivity (95% CI)/Specificity (95% CI)   Comparison
  ---------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ----------------------------------------------- ------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Patients with HF symptoms (dyspnea)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Mean E/è                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Penicka et al (2010)[38](#jah31280-bib-0038){ref-type="ref"} (N=30)          NYHA functional class II/III dyspnea and LVEDP \>16 mm Hg at baseline or after hemodynamic interventions (N=20)                                       NYHA functional class II/III dyspnea and LVEDP \<16 mm Hg at baseline or after hemodynamic interventions (N=10)                                                           ---                 \>13[a](#jah31280-note-0013){ref-type="fn"}     30 (14--53)/90 (54--99)                     HFpEF vs controls
  Weber et al (2013)[49](#jah31280-bib-0049){ref-type="ref"} (N=359)           Definite HFpEF: dyspnea on exertion and LVEDP \>16 mm Hg and NT‐proBNP \>220 pg/mL (N=71)                                                             Possible HFpEF: dyspnea on exertion not meeting criteria for definite HFpEF (N=223); no HFpEF: (dyspnea on exertion but LVEDP ≤12 mm Hg and NT‐proBNP ≤120 pg/mL (N=65)   0.62 (0.57--0.67)   ---                                             ---                                         Definite HFpEF vs controls (combined possible HFpEF and no HFpEF)
  Weber et al (2013)[49](#jah31280-bib-0049){ref-type="ref"} (N=136, of 359)   Definite HFpEF: see above (N=71)                                                                                                                      No HFpEF: see above (N=65)                                                                                                                                                0.8 (0.72--0.87)    ---                                             ---                                         Definite HFpEF vs no HFpEF (possible HFpEF N=223, were not included in this analysis)
  Lateral E/è                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Penicka et al (2010)[38](#jah31280-bib-0038){ref-type="ref"} (N=30)          NYHA functional class II/III dyspnea and LVEDP \>16 mm Hg at baseline or after hemodynamic interventions (N=20)                                       NYHA functional class II/III dyspnea and LVEDP \<16 mm Hg at baseline or after hemodynamic interventions (N=10)                                                           ---                 \>12[a](#jah31280-note-0013){ref-type="fn"}     40 (21--62)/80 (46--95)                     HFpEF vs controls
  Arques et al (2005)[21](#jah31280-bib-0021){ref-type="ref"} (N=38)           Clinical criteria for CHF and LVEDP ≥15 mm Hg (N=18)                                                                                                  Acute dyspnea the result of noncardiac cause, BNP \<150 pg/mL, not meeting Framingham criteria for CHF (no invasive confirmation performed) (N=20)                        0.92 (0.84--1.0)    \>11[b](#jah31280-note-0014){ref-type="fn"}     78 (53--90)/100 (71--100)                   HFpEF vs controls
  Septal E/è                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Penicka et al (2010)[38](#jah31280-bib-0038){ref-type="ref"} (N=30)          NYHA class II/III dyspnea and LVEDP \>16 mm Hg at baseline or after hemodynamic interventions (N=20)                                                  NYHA class II/III dyspnea and LVEDP \<16 mm Hg at baseline or after hemodynamic interventions (N=10)                                                                      ---                 \>15[a](#jah31280-note-0013){ref-type="fn"}     21 (9--44)/96 (55--100)                     HFpEF vs controls
  Weber et al (2006)[25](#jah31280-bib-0025){ref-type="ref"} (N=58, of 235)    Definite HFpEF: dyspnea and LVEDP \>16 mm Hg and NT‐proBNP \>125 pg/mL (N=29)                                                                         Dyspnea and LVEDP ≤16 mm Hg and NT‐proBNP ≤125 pg/mL (N=29)                                                                                                               0.75 (0.62--0.86)   ---                                             ---                                         HFpEF vs controls
  Weber et al (2013)[49](#jah31280-bib-0049){ref-type="ref"} (N=359)           Definite HFpEF: dyspnea on exertion, LVEDP \>16 mm Hg, NT‐proBNP \>220 pg/mL (N=71)                                                                   Possible HFpEF: dyspnea on exertion not meeting criteria for definite HFpEF (N=223): no HFpEF: dyspnea on exertion but LVEDP ≤12 mm Hg and NT‐proBNP ≤120 pg/mL (N=65)    0.75 (0.70--0.79)   ---                                             ---                                         Definite HFpEF vs controls (combined possible HFpEF and no HFpEF)
  Weber et al (2013)[49](#jah31280-bib-0049){ref-type="ref"} (N=136, of 359)   Definite HFpEF (N=71): see above                                                                                                                      No HFpEF (N=65): see above                                                                                                                                                0.82 (0.75--0.88)   ---                                             ---                                         Definite HFpEF vs no HFpEF (possible HFpEF N=223 were not included in this analysis)
  HFpEF patients vs no HF symptoms patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Lateral E/è                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Kasner et al (2007)[26](#jah31280-bib-0026){ref-type="ref"} (N=55)           Dyspnea, exercise intolerance, τ \>48 ms, and LVEDP ≥12 mm Hg, and/or β \>0.015 mL^−1^ and/or *b* \>0.19 mm Hg/mL (N=43)                              Chest discomfort, no HF symptoms, no significant heart disease (N=12)                                                                                                     0.91 (--)           \>8[b](#jah31280-note-0014){ref-type="fn"}      83 (70--92)/92 (59--99)                     HFpEF vs controls
  Kasner et al (2010)[37](#jah31280-bib-0037){ref-type="ref"} (N=33)           Dyspnea, exercise intolerance, and LVEDP ≥16 mm Hg τ \>48 ms and, and/or β \>0.015 mL^−1^ and/or *b* \>0.19 mm Hg/mL (N=21)                           Chest discomfort, no HF symptoms, no significant heart disease (N=12)                                                                                                     0.83 (--)           ---                                             ---                                         HFpEF vs controls
  Kasner et al (2011)[41](#jah31280-bib-0041){ref-type="ref"} (N=180)          Dyspnea, exercise intolerance, and LVEDP ≥12 mm Hg or τ ≥48 ms or dP/dt~min~ ≥−1100 mm Hg/s or PCWP \>12 mm Hg or PCWP‐at‐stress \>20 mm Hg (N=107)   Chest discomfort, no HF symptoms, no significant heart disease (N=73)                                                                                                     0.86 (--)           ---                                             ---                                         HFpEF vs controls
  DD patients vs no DD patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Septal E/è                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Weber et al (2006)[25](#jah31280-bib-0025){ref-type="ref"} (N=126, of 235)   Definite DD: LVEDP\>16 mm Hg and NT‐proBNP \> 125 pg/mL (N=44)                                                                                        LVEDP ≤16 mm Hg and NT‐proBNP ≤125 pg/mL (N=82)                                                                                                                           0.78 (0.69--0.87)   \>11.2[b](#jah31280-note-0014){ref-type="fn"}   73 (58--84)/73 (63--82)                     Definite DD vs controls (possible DD N=109 (LVEDP \>16 mm Hg or NT‐proBNP \>125 pg/mL) were not included)

Empty cells are the result of no available data. CHF indicates congestive heart failure; dP/dt~min~, the minimum rate of pressure change in the left ventricle; HF, heart failure; DD, diastolic dysfunction; LVEDP, left ventricular end‐diastolic pressure; N, number of patients; NT‐proBNP, the N‐terminal of the prohormone brain natriuretic peptide; NYHA, New York Heart Association; PCWP, pulmonary capillary wedge pressure; pEF, preserved ejection fraction; ROC AUC, area under receiver operating characteristic curve.

American Society of Echocardiography--recommended cutoff values.

Optimal cutoff values.

LV Relaxation Time Constant (τ) and LV Chamber Stiffness {#jah31280-sec-0027}
--------------------------------------------------------

Only 1 study[26](#jah31280-bib-0026){ref-type="ref"} reported a relationship between E/è~lateral~ and τ. Low correlation of E/è~lateral~ with τ (*r*±SE 0.34±0.13) was found.[26](#jah31280-bib-0026){ref-type="ref"} Two studies[26](#jah31280-bib-0026){ref-type="ref"}, [37](#jah31280-bib-0037){ref-type="ref"} from the same group of investigators assessed the relationship of E/è~lateral~ with LV chamber stiffness. There was a moderate correlation of E/è~lateral~ with LV stiffness parameters in both studies[26](#jah31280-bib-0026){ref-type="ref"}, [37](#jah31280-bib-0037){ref-type="ref"} (average *r*±SD 0.59±0.08 for β \[mL^−1^\] and 0.54±0.11 for *b* \[mm Hg/mL\]). These 2 studies had a high risk of bias and applicability for patient selection domain on the Quality Assessment of Diagnostic Accuracy Studies analysis (Table [3](#jah31280-tbl-0003){ref-type="table-wrap"}).

Discussion {#jah31280-sec-0028}
==========

To best of our knowledge, this is the first comprehensive meta‐analysis of the diagnostic accuracy of tissue Doppler echocardiographic index, E/è, to estimate LVFP in patient cohorts with pEF and for the identification of DD/HFpEF. We find that the evidence for the use of E/è for routine clinical practice in estimating LVFP in pEF is limited. Further, because of multiplicity of study designs, no conclusive inference can be drawn for the use of E/è in diagnosing DD/HFpEF in routine clinical applications.

Based on ASE and ESC guidelines,[4](#jah31280-bib-0004){ref-type="ref"}, [5](#jah31280-bib-0005){ref-type="ref"} E/è is an important noninvasive parameter with which to evaluate diastolic function. From a clinical perspective, this application of E/è can be grouped into 2 important concepts: (1) estimation of LVFP---this includes either semiquantitative estimate of LVFP (ie, normal versus elevated) and/or direct quantitative estimate of LVFP, and (2) clinical diagnosis of DD/HFpEF. Extensive use of E/è as a noninvasive surrogate for LVFP and diastolic function has been observed in recent clinical research in cardiac and multidisciplinary fields.[6](#jah31280-bib-0006){ref-type="ref"}, [7](#jah31280-bib-0007){ref-type="ref"}, [8](#jah31280-bib-0008){ref-type="ref"}, [52](#jah31280-bib-0052){ref-type="ref"}, [53](#jah31280-bib-0053){ref-type="ref"}, [54](#jah31280-bib-0054){ref-type="ref"} The poor‐to‐mediocre correlation of E/è to LVFP indicates that E/è alone may not be reliable to estimate LVFP. Therefore, its use for directly estimating LVFP is not recommended until well validated in robust clinical studies.

For the semiquantitative estimate of LVFP, we find that (1) the summary specificity of the ASE‐recommended E/è for identifying elevated LVFP is high but the summary sensitivity is very low. Except for E/è~septal~, the resulting LR^+^ is also low. (2) For identifying normal LVFP, the LR^+^ of E/è is low for all locations. To provide a practical framework for interpreting/use of these findings in the clinical practice, we describe 3 representative scenarios based on E/è~septal~ that demonstrates the best LR^+^ for identifying elevated LVFP. These scenarios are based on PPV--patient prevalence relationship obtained in our study results (Figures [3](#jah31280-fig-0003){ref-type="fig"}I and [4](#jah31280-fig-0004){ref-type="fig"}I).

Scenario 1: Low Prevalence of Elevated LVFP {#jah31280-sec-0029}
-------------------------------------------

Here, E/è~septal~ \<8 generally suggests normal LVFP, while E/è \>15 may be misleading (Figure [5](#jah31280-fig-0005){ref-type="fig"}A). However, the E/è~septal~ \<8 value is found only in a small subset with a large number of patients in indeterminate zone. This is consistent with previous reported observations of E/è that has a broad range of values in healthy people with evidence of increasing E/è with age.[55](#jah31280-bib-0055){ref-type="ref"}, [56](#jah31280-bib-0056){ref-type="ref"} In our analyzed cohorts, the majority of whom underwent clinically recommended cardiac catheterization, only 36% to 64% with normal LVFP were noted to have E/è \<8 (Figure [4](#jah31280-fig-0004){ref-type="fig"}). In the community setting, disease prevalence of confirmed HFpEF is low (≈1%) in adults \>45 years old, whereas moderate to severe DD with pEF is estimated at \<6%.[1](#jah31280-bib-0001){ref-type="ref"} Therefore, routine use of estimating E/è to evaluate elevated LVFP or DD in ambulatory clinical situations requires further testing and validation.

![Estimates for use of American Society of Echocardiography--recommended E/è~septal~ cutoffs in patient group with varying prevalences of elevated left ventricular filling pressure (LVFP). A through C, Summary outline of application of E/è~septal~ for evaluating elevated and normal LVFP in representative examples with disease prevalence of elevated LVFP set at 10%, 50%, and 90% for n=100. More than half of the patients are in the indeterminate zone regardless of the disease prevalence. In the low‐prevalence (A, 10%) scenario, abnormal E/è is noted in a few patients and can be misleading in a substantial number of these patients. Normal E/è value is suggestive of normal LVFP in the majority of patients. For intermediate prevalence (B, 50%), abnormal E/è is suggestive of elevated LVFP, while normal E/è value is suggestive of normal LVFP in the majority of patients. In the high‐prevalence (C, 90%) scenario, even more patients are found in the indeterminate zone. Abnormal E/è is suggestive of elevated LVFP in most instances. Normal E/è is misleading in most cases here and cannot be used to rule out elevated LVFP. D and E, Estimated 2×2 distributions of patients after application of E/è~septal~ cutoffs with hierarchical summary receiver operating characteristic--calculated summary sensitivity and specificity for evaluating elevated (D) or normal (E) LVFP (Figures [3](#jah31280-fig-0003){ref-type="fig"} and [4](#jah31280-fig-0004){ref-type="fig"}).](JAH3-5-e002530-g005){#jah31280-fig-0005}

Scenario 2: High Prevalence of Elevated LVFP {#jah31280-sec-0030}
--------------------------------------------

Here E/è~septal~ \>15 generally suggests elevated LVFP, while E/è~septal~ \<8 may be misleading (Figure [5](#jah31280-fig-0005){ref-type="fig"}C). Further, this abnormal E/è finding will be present only in a small subset of patients with elevated LVFP. Based on our analysis, we find that only 24% to 44% with elevated LVFP have increased E/è (Figure [3](#jah31280-fig-0003){ref-type="fig"}) and, importantly, 10% to 26% patients with elevated LVFP have normal E/è \<8 (Figure [4](#jah31280-fig-0004){ref-type="fig"}). Similar observations have been made in the clinical trials of proven HFpEF where ≈30% have no echocardiographic evidence of DD.[57](#jah31280-bib-0057){ref-type="ref"}

Scenario 3: Intermediate Prevalence of Elevated LVFP {#jah31280-sec-0031}
----------------------------------------------------

Here E/è~septal~ values \>15 or \<8 may correctly identify about one‐third of total patients with either elevated or normal LVFP. More than half would remain in the indeterminate zone, and some would be falsely classified (Figure [5](#jah31280-fig-0005){ref-type="fig"}B).

Significance of Intermediate E/è Zone {#jah31280-sec-0032}
-------------------------------------

According to ASE and ESC recommendations, additional echocardiographic indices should be used to estimate LVFP when E/è falls into intermediate zone (8\< E/è \<12--15).[4](#jah31280-bib-0004){ref-type="ref"}, [5](#jah31280-bib-0005){ref-type="ref"} Thus, based on our analysis, more than half of the patients (eg, 50--75% for E/è~septal~; Figure [5](#jah31280-fig-0005){ref-type="fig"}) would require additional indices. ASE guidelines state that "an Ar--A duration ≥30 ms, a change of E/A ratio with the Valsalva maneuver of ≥0.5, IVRT/T~E‐è~ \<2, PA systolic pressure ≥35 mm (in the absence of pulmonary disease), and maximal LA volume ≥34 mL/m^2^ are all indicative of increased LV filling pressures".[4](#jah31280-bib-0004){ref-type="ref"} In the current work, we did not analyze incremental power of other echocardiographic indices that might favor the diagnostic accuracy of E/è. Because of the complexity of the topic, such analysis would require separate studies. We should, however, point out that by using broad search terminology in our search terms, we found very few studies[27](#jah31280-bib-0027){ref-type="ref"}, [33](#jah31280-bib-0033){ref-type="ref"}, [34](#jah31280-bib-0034){ref-type="ref"}, [35](#jah31280-bib-0035){ref-type="ref"}, [43](#jah31280-bib-0043){ref-type="ref"} that addressed this aspect in their studies. Most of them have similar study limitations as just given here (mostly with low patient cohort and heterogeneous design). Based on our study results that demonstrate the uncertainty of using the proposed E/è cutoffs, we suggest that the additional echocardiographic parameters described here (and probably others) should be evaluated across the range of E/è values and not restricted to the intermediate zone to define an optimal approach to evaluate LVFP and identify HFpEF in prospective studies. Recently, 1 such clinical trial has been proposed.[58](#jah31280-bib-0058){ref-type="ref"}

Application of E/è in DD/HFpEF {#jah31280-sec-0033}
------------------------------

Invasive characterization of DD relies on LV end‐diastolic pressure--volume relationship. A single measure of LVFP (eg, LVEDP) does not comprehensively characterize the diastolic properties. LV chamber stiffness is an accepted invasive method to accurately characterize LV diastolic function. Therefore, one can suggest that for accurate diagnostics of DD by E/è, there should also be a relationship between E/è and LV chamber stiffness. Based on our results, the relationship of E/è to LV chamber stiffness is not well established. We found only 2 studies[26](#jah31280-bib-0026){ref-type="ref"}, [37](#jah31280-bib-0037){ref-type="ref"} that directly compared E/è with LV chamber stiffness. These studies have significant limitations for wider applicability. Therefore, more clinical research is needed before E/è can be recommended as a surrogate for LV chamber stiffness.

The current consensus for the diagnosis of HFpEF relies on the clinical presentation and exclusion of other etiologies. In clinical practice, echocardiography is frequently used to evaluate HFpEF. There are only a small number of studies that have compared the diagnostic accuracy of E/è to evaluate clinical DD/HFpEF. These studies have significant methodological limitations such as lack of uniform reference definition and case‐control design. On area under the ROC curve analysis, although the E/è values appear to be moderate to high in identifying DD/HFpEF, the clinical applicability is again limited. Based on our analysis, no uniform/summary cutoff E/è value can be recommended.

Limitations {#jah31280-sec-0034}
-----------

We performed analysis based on the published data sets and did not have access to the primary data source. Some studies did not provide the quantitative data set required for our analysis, which, in some instances, was because of a lack of statistically meaningful relationships. This suggests that our results are affected to some extent by the publication bias. Formal assessment of publication bias was not performed as the number of studies is inadequate in individual groups. Despite our best efforts, in some studies we find that the data points extracted from the graphs did not match the original sample size (Figures [3](#jah31280-fig-0003){ref-type="fig"} and [4](#jah31280-fig-0004){ref-type="fig"}). This discordance is of small magnitude and could be the result of an inaccurate number of plotted data points and/or superimposed data points. In many studies, the timing of echocardiographic and invasive measurements was not simultaneous. It has been shown that the LVFP can rapidly change based on underlying hemodynamic status.[59](#jah31280-bib-0059){ref-type="ref"} Because all measurements were performed at the rest, mostly on the same day if not simultaneously, the hemodynamic conditions are expected to be similar. Overall, we find that our study results remained similar regardless of the timing of invasive and echocardiographic measurements.

We grouped studies that were not identical in study design and methods as using strict criteria would have excluded a large number of studies from the analysis and therefore made any analysis pointless. For similar reasons, including a lack of comparable and comprehensive data sets, we were unable to perform statistically meaningful subgroup analysis to evaluate possible causes for heterogeneity in correlation coefficients, sensitivity, and specificity among the studies. We have provided all the raw data that we have extracted from the selected studies that could be used in future meta‐analysis or in preparation of specific projects (eg, for assessment of a sample size).

Conclusions {#jah31280-sec-0035}
===========

There is insufficient evidence to support that E/è can reliably estimate LVFP in patients with preserved LVEF. The diagnostic accuracy of E/è to predict LVFP and evaluate DD/HFpEF is limited. Its routine clinical use requires rigorous evaluation in well‐designed prospective multicenter studies.

Sources of Funding {#jah31280-sec-0037}
==================

This work was supported by National Institutes of Health grant NHLBI R01‐HL104018 (Dr Gupta). The funding organizations did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclosures {#jah31280-sec-0038}
===========

None.

Supporting information
======================

###### 

**Appendix S1.** Study protocol.

**Appendix S2.** Data sources and search strategy.

**Appendix S3.** QUADAS‐2 questionnaire.

**Appendix S4.** Excluded full‐text studies.

**Appendix S5.** Secondary analysis of E/è correlation with LVFP.

**Appendix S6.** Secondary analysis of sensitivity/specificity of E/è cutoffs to predict elevated LVFP.

**Appendix S7.** Optimal cutoffs and AUC for elevated LVFP.

**Appendix S8.** Secondary analysis of sensitivity/specificity of E/è cutoffs to predict normal LVFP.

###### 

Click here for additional data file.

We thank Lee A. Vucovich, MLS, MS, AHIP, Assistant Director for Reference Services, UAB Lister Hill Library, for her valuable assistance with search strategy.
